table – Page 6 – Communicable Diseases Research

A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-10-062022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

An IoT-based framework for early identification and monitoring of COVID-19 cases

Research article

Published on 2020-09-012022-10-05
Journal: Biomedical Signal Processing and Control [Category] 치료기술,

The Role of Virtual Consultations in Plastic Surgery During COVID-19 Lockdown

Original Article

Published on 2020-08-312022-10-27
Journal: Aesthetic Plastic Surgery [Category] Coronavirus, MERS, SARS,

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 active cancer acute respiratory distress acute respiratory distress syndrome Adult patients advance directives Advanced cancer age alpha error anticipated approved ARDS assessment assigned bilateral pulmonary infiltrates Blinding block breast-feeding Buenos Aires capture cardiac disease CEMIC clinical clinical trial code Complete concealed Confirmed COVID-19 COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids delirium develop Dexamethasone diagnosis of SARS-CoV-2 directive discharge disease dissemination do not resuscitate dose Effectiveness element End-Expiratory Pressure evaluate exclusion criteria Expiratory Pressure explained failure followed by Frequency glucocorticoid Glucocorticoids group hemodynamic High dose HIV infection hypoxemic Hypoxemic respiratory failure ICU Immunosuppression Immunosuppressive agents include inclusion criteria Infection Informed consent intensive care unit International legal guardian Length less Life expectancy local Ethics Committee mechanical ventilation Mortality multicenter muscle weakness Nosocomial infection Nosocomial infections number objective open open label open trial other disease other diseases outcome Palliative care PaO parallel group participant Participation Patient Patient care platform Pneumonia Positive end-expiratory pressure power power of 80% Prednisone pressure Prone position protocol R language random randomised randomised controlled trial randomization Randomized randomized clinical trial receive recruitment Registered renal renal disease respiratory respiratory distress Respiratory distress syndrome Respiratory failure resuscitate order RT-PCR Sample size SARS-COV-2 infection SARS-CoV-2 pneumonia secondary Secondary outcomes secondary to sequence Sequential Organ Failure Assessment severe immunosuppression SOFA Standard deviation status Stratified randomization Study protocol subject Support syndrome table terminal Terminal disease title Treatment treatment groups Trial Trial registration two-tailed alpha error Variation ventilator ventilator-free day Ventilator-free days ventilatory Version viral shedding weakness website women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season

Recommendations and Reports

Published on 2020-08-212022-10-30
Journal: MMWR Recommendations and Reports [Category] COVID-19, Fulltext, 신종인플루엔자,

[키워드] Admission allergy alleviate antiviral medication Care caused Cell change circulation Committee components concerning contraindication contraindications Control coronavirus disease COVID-19 described document drug expected food Health hospitalizations illnesses include indications Influenza influenza vaccination influenza vaccine influenza vaccines information intensive care Lineage MOST Novel coronavirus pandemic Practice Precaution Prevalence prevention Quadrivalent receive recommendation reduce reduction reduction in routine SARS-CoV-2 season seasonal Seasonal influenza second severity Stress Symptom table the United State The United States trivalent United States vaccination Vaccine website
[DOI] 10.15585/mmwr.rr6908a1 PMC 바로가기 [Article Type] Recommendations and Reports

Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial

Study Protocol

Published on 2020-07-062022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Abnormalities absence Ascorbate assigned baseline Biotin block BMI body temperature Chemotherapy clinical clinical trial clinical trials Complete condition control group COVID-19 CRP CT scan definitive diagnosis dissemination Duration element eligible patient ESR evaluate exclusion criteria expected female patient Folic acid Gender HIV Hospitalization Hypothesis ICU ICU patient IL6 Imam Impact IMPROVE include inclusion criteria intensive care unit Intervention invasive Iran kidneys liver lung male mortality rate New nicotinamide Non-invasive number objective organ outcome oxygen saturation pantothenate parallel group participant participated Patient patients patients with COVID-19 PCR per day percentage phosphate Placebo polymerase chain protocol pulmonary involvement randomization Randomized Randomized controlled trial Randomly receive registry renal researcher respiratory Riboflavin Sample size severity significantly sodium SpO2 Study protocol Supplementation Support table Tehran the patient thiamine nitrate TNF-α Treatment Two-arm viral disease Vitamin vitamin A Vitamin B Vitamin C Vitamin D Vitamin E WBC website weight with COVID-19
[DOI] 10.1186/s13063-020-04547-0 PMC 바로가기 [Article Type] Study Protocol

ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-022022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] active treatment phase Amiodarone anticipated Arm ARMS assessment baseline blinded Block randomisation block size Blood Group Breastfeeding Cambridge Care Chemoprophylaxis Chloroquine Chronic kidney disease ciprofloxacin clarithromycin clinical clinical testing Compliance Contact coronavirus disease COVID-19 COVID-19 case COVID-19 disease COVID-19 disease severity COVID-19 infection COVID-19 patients criteria current cyclosporin Daily Daily-dosing Date Day deficiency defined described determine diagnosed with COVID-19 Diagnosis digoxin disease dissemination dose dosed element enrolled enrolment epilepsy EU Clinical Trial EudraCT evaluated Factor File fluconazole Follow-up foundation frontline healthcare workers G6PD Genetic Glucose-6-phosphate halofantrine HCQ healthcare Healthcare workers heart failure hospital Hydroxychloroquine hypersensitivity reaction increase Infection Intervention investigator Laboratory Liver disease maintenance Matched mefloquine moxifloxacin National Health Service NHS number objective oral outcome participant Participants Patient patients with COVID-19 pharmacokinetic phase Placebo placebo tablet placebo-controlled trial porphyria positive COVID-19 positive individual Positive test Praziquantel predicted Prevent problem prochlorperazine protocol randomised randomised controlled trial recruited recruitment regimen Registered reported Research Retinal disease Sample size Secondary objective serology serum biomarker Standard statistical analysis status Stratification stratified Study protocol susceptibility symptoms onset syndrome table Tablet tablets time Treatment treatment period Trial Trust university Variation website Weekly Weekly-dosing work
[DOI] 10.1186/s13063-020-04543-4 PMC 바로가기 [Article Type] Letter

Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M pro )

Article

Published on 2020-06-292022-10-29
Journal: Microorganisms [Category] COVID-19,

COVID-19 and smoking: A systematic review of the evidence

Editorial

Published on 2020-03-202022-10-28
Journal: Tobacco Induced Diseases [Category] COVID-19,

[키워드] 2019 novel coronavirus 2019-nCoV Admission adverse outcome adverse outcomes Analysis association assumed autonomous available data calculate Care changes in Characteristics chest radiology China clinical Clinical characteristics Clinical outcome clinical symptom clinically cohort study conducted coronavirus Course COVID-19 COVID-19 pandemic current database death deaths detrimental diagnosed died discharged disease Disease progression English epidemiological evaluate Evidence Factor feature FIVE former Health hospital hospitalisation hospitalised patient Hospitalization humans ICU ICU care immune system inclusion criteria Increases indicated individual infected with COVID-19 infected with SARS-CoV-2 infections Infectious disease Influenza information Inpatient intensive care Italy Laboratory laboratory-confirmed Logistic regression Logistic regression analysis lung majority mechanical ventilation MERS-CoV Mortality mortality risk factor multicenter cohort study multicentre multivariate multivariate logistic regression negative non-ICU non-severe patient non-survivor outbreak outcome pandemic Patient patients patients died patients with COVID-19 percentage plethora Population positive previous study Prognosis Prognostic factor progression proportion Prospective provided pulmonary ranged Region regions reported Research Respiratory disease retrieved retrospective retrospective cohort study risk factor Sample size searched setting Severe case Severe patient severe symptom severe symptoms severity shown significantly higher small sample size smoker Smokers smoking smoking status statistical analysis statistically significant statistically significant difference Study design study population Support survived survivor Symptom Symptoms systematic review table tested the disease the patient those that survived title Tobacco two group were excluded were used with COVID-19 Wuhan Wuhan, China
[DOI] 10.18332/tid/119324 PMC 바로가기 [Article Type] Editorial